Louis Picker, M.D., professor in OHSU’s Vaccine & Gene Therapy Institute, investigates the potential of cytomegalovirus-based vaccines. With colleagues Klaus Früh, Ph.D., and Scott Hansen, Ph.D., both in VGTI, they have found their vaccine platform shows promise as a “shield” against cancer.

In a new study, Klaus Früh, Ph.D., left, Louis Picker, M.D., and Scott Hansen, Ph.D., all in OHSU’s Vaccine & Gene Therapy Institute, show that their platform for cytomegalovirus-based vaccines shows promise as a “shield” against cancer. (OHSU/Christine Torres Hicks)

Postdoctoral researcher Cristina Espinosa runs an experiment, November 16, 2016. The early evidence found in research at OHSU by Espinosa, Dr. Sudarshan Anand and his team is promising, suggesting there may be a panel of microRNA that can be used as a biomarker for radiation therapy for many types of cancer in the future.
(OHSU/Kristyna Wentz-Graff)

Postdoctoral researcher Cristina Espinosa runs an experiment, November 16, 2016. The early evidence found in research at OHSU by Espinosa, Dr. Sudarshan Anand and his team is promising, suggesting there may be a panel of microRNA that can be used as a biomarker for radiation therapy for many types of cancer in the future.
(OHSU/Kristyna Wentz-Graff)

The early evidence from research by Dr. Sudarshan Anand and his team at OHSU is promising, suggesting there may be a panel of microRNA that can be used as a biomarker for radiation therapy for many types of cancer in the future.
(OHSU/Kristyna Wentz-Graff)

Postdoctoral researcher Cristina Espinosa runs an experiment, November 16, 2016. The early evidence found in research at OHSU by Espinosa, Dr. Sudarshan Anand and his team is promising, suggesting there may be a panel of microRNA that can be used as a biomarker for radiation therapy for many types of cancer in the future.
(OHSU/Kristyna Wentz-Graff)

Dr. Sudarshan Anand (left) and postdoctoral researcher Cristina Espinosa in their lab, November 16, 2016. The early evidence from research by Dr. Sudarshan Anand and his team at OHSU is promising, suggesting there may be a panel of microRNA that can be used as a biomarker for radiation therapy for many types of cancer in the future.
(OHSU/Kristyna Wentz-Graff)

Postdoctoral researcher Cristina Espinosa runs an experiment, November 16, 2016. The early evidence found in research at OHSU by Espinosa, Dr. Sudarshan Anand and his team is promising, suggesting there may be a panel of microRNA that can be used as a biomarker for radiation therapy for many types of cancer in the future.
(OHSU/Kristyna Wentz-Graff)